THE ECONOMIC IMPACT OF SWITCHING TO HERCEPTIN (TRASTUZUMAB) BIOSIMILAR FOR THE TREATMENT OF METASTATIC BREAST CANCER FROM A UK PAYER PERSPECTIVE
Author(s)
Brown D, Bozkaya D
Xcenda, LLC, Palm Harbor, FL, USA
OBJECTIVES: Herceptin (trastuzumab) is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) as a monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Currently, there are four Herceptin biosimilars under review by the EMA. The aim of the study was to evaluate the economic impact of switching to the Herceptin biosimilar product in patients with MBC from a UK payer perspective. METHODS: A one-year budget impact model was created in Microsoft Excel to calculate the number of patients in the UK who can receive the biosimilar for MBC. Incident and prevalent populations were both eligible to receive the biosimilar, with a 50% uptake among incident patients, and 25% uptake among prevalent patients. MBC incidence and prevalence rates, and population and treatment characteristics were taken from available literature. Only drug costs were included as the same efficacy and safety was assumed for trastuzumab and the biosimilar. Trastuzumab cost was obtained from the British National Formulary; a 20% discount was assumed with the biosimilar. Patients were assumed to be on treatment without breaks in the base-case scenario. RESULTS: Among the 25,809 patients estimated to be on treatment for MBC, 6,999 (25%) were predicted to receive the biosimilar, resulting in a cost reduction of £ CONCLUSIONS: The results from this economic assessment suggest that the introduction of the biosimilar could lead to considerable savings in the UK. These findings should be evaluated in light of actual treatment and prescribing patterns, and patient preferences.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PCN74
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis, Cost/Cost of Illness/Resource Use Studies
Disease
Oncology